Kaplan, D.E.; Tan, R.; Xiang, C.; Mu, F.; Hernandez, S.; Ogale, S.; Li, J.; Lin, Y.; Shi, L.; Singal, A.G.
Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database. Cancers 2024, 16, 3508.
https://doi.org/10.3390/cancers16203508
AMA Style
Kaplan DE, Tan R, Xiang C, Mu F, Hernandez S, Ogale S, Li J, Lin Y, Shi L, Singal AG.
Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database. Cancers. 2024; 16(20):3508.
https://doi.org/10.3390/cancers16203508
Chicago/Turabian Style
Kaplan, David E., Ruoding Tan, Cheryl Xiang, Fan Mu, Sairy Hernandez, Sarika Ogale, Jiayang Li, Yilu Lin, Lizheng Shi, and Amit G. Singal.
2024. "Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database" Cancers 16, no. 20: 3508.
https://doi.org/10.3390/cancers16203508
APA Style
Kaplan, D. E., Tan, R., Xiang, C., Mu, F., Hernandez, S., Ogale, S., Li, J., Lin, Y., Shi, L., & Singal, A. G.
(2024). Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib as First-Line Therapy: Findings from the National Veterans Health Administration Database. Cancers, 16(20), 3508.
https://doi.org/10.3390/cancers16203508
